For research use only. Not for therapeutic Use.
VN339(CAT: I038090) is a selective and potent agonist of the thyroid hormone receptor β (THRβ), extensively studied in metabolic and cardiovascular research. By targeting THRβ, VN339 demonstrates potential in modulating lipid metabolism, promoting cholesterol reduction, and improving metabolic homeostasis. This compound is widely used to explore therapeutic strategies for conditions such as hypercholesterolemia, nonalcoholic fatty liver disease (NAFLD), and obesity. Its receptor specificity minimizes off-target effects, offering a safer profile for preclinical investigations. VN339 provides researchers with a reliable tool to dissect THRβ-related pathways and advance the development of novel treatments for metabolic disorders.
Catalog Number | I038090 |
Synonyms | VN339; VN-339; VN 339 |
Molecular Formula | C22H16N4O |
Purity | 98% |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | 1-Methyl-4-(9-(3-(pyridin-4-yl)-phenyl)-7-oxa-2-aza-bicyclo[4.3.0]nona-1,3,5,8-tetraen-3-yl)-1H-pyrazole |
InChI | InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3 |
InChIKey | HEAGNKNMQVIVMM-UHFFFAOYSA-N |
SMILES | CN1N=CC(C2=CC=C3OC=C(C4=CC=CC(C5=CC=NC=C5)=C4)C3=N2)=C1 |